# Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

> **NCT06959095** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 981 (estimated)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Depemokimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06959095
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2029-08-20
- **Final completion:** 2029-08-20
- **Target enrollment:** 981 (ESTIMATED)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959095, "Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06959095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*